Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FT576 |
Synonyms | |
Therapy Description |
FT576 are iPSC-derived CAR-NK cells that have been engineered to express a recombinant IL-15/IL-15 receptor signaling complex, a high-affinity, non-cleavable CD16, and a chimeric antigen receptor targeted against BCMA, and to eliminate CD38 expression, which may lead to tumor regression and growth delay (Cancer Res 2021;81(13_Suppl):Abstract nr 1550). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FT576 | FT-576|FT 576 | FT576 are iPSC-derived CAR-NK cells that have been engineered to express a recombinant IL-15/IL-15 receptor signaling complex, a high-affinity, non-cleavable CD16, and a chimeric antigen receptor targeted against BCMA, and to eliminate CD38 expression, which may lead to tumor regression and growth delay (Cancer Res 2021;81(13_Suppl):Abstract nr 1550). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05182073 | Phase I | Cyclophosphamide + Fludarabine FT576 Daratumumab + FT576 | FT576 in Subjects With Multiple Myeloma | Active, not recruiting | USA | 0 |